RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nykode Therapeutics A Stock

Nykode Therapeutics A Employees 2024

Nykode Therapeutics A Employees

36

Ticker

NYKD.OL

ISIN

NO0010714785

WKN

A2PZ5J

In 2024, Nykode Therapeutics A employed 36 people, a 0% change from the 36 number of employees in the previous year.

Nykode Therapeutics A Aktienanalyse

What does Nykode Therapeutics A do?

Vaccibody AS is a Norwegian biotechnology company that was founded in 2007. It is headquartered in Oslo and currently employs about 40 people. The company specializes in the development of individualized vaccines based on DNA-based technology. The idea for founding Vaccibody came about when the two founders, Agnete Fredriksen and Bjarne Bogen, were collaborating at the University of Oslo. They wanted to develop a method to personalize vaccines in order to increase their effectiveness and compatibility. Their discovery is based on the fact that T-cells play an important role in the immune system and can recognize specific target proteins produced by cancer cells or viruses. Vaccibody's business model is based on the development of individualized vaccines based on DNA-based technology. The company has several different areas, including cancer immunotherapy, infectious diseases, and personalized medicine. Vaccibody's vaccines can be used for various types of cancer, such as lung, breast, and prostate cancer. Vaccibody offers a range of products, including a vaccine against HPV (human papillomavirus) that is approved for women aged 9 to 45. This vaccine aims to reduce the risk of cervical cancer. Another product from Vaccibody is the prostate cancer vaccine VCD-001. This vaccine uses the antigen PSA (prostate-specific antigen), which occurs on the surface of prostate cancer cells, to stimulate the patient's immune system. Vaccibody is also working on the development of vaccines against COVID-19 and has already achieved initial positive results in preclinical studies. As part of its personalized medicine division, Vaccibody offers the DNA platform VACCIBODY®, which is used to manufacture individualized DNA vaccines. This technology allows the vaccine to be tailored specifically to the needs of each patient. Vaccibody has achieved many important milestones since its inception. In 2018, the company received a $12.5 million investment to further develop its cancer immunotherapy platform. In 2020, Vaccibody received an additional $43.5 million investment to advance the development of its COVID-19 vaccine. Overall, Vaccibody has the potential to change the way vaccines are developed and used. DNA-based technology offers many advantages over conventional vaccines, especially in personalized medicine. Vaccibody is working hard to further develop its technology and bring its products to market in order to improve the lives of people around the world. Nykode Therapeutics A ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Nykode Therapeutics A's Employee Base

Nykode Therapeutics A's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Nykode Therapeutics A's operational capacity and future potential.

Year-to-Year Comparison

Assessing Nykode Therapeutics A's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Nykode Therapeutics A's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Nykode Therapeutics A’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Nykode Therapeutics A stock

How many employees does Nykode Therapeutics A have this year?

Nykode Therapeutics A has 36 undefined employees this year.

How many employees did Nykode Therapeutics A have compared to the previous year?

Compared to the previous year, Nykode Therapeutics A had 0% more employees.

What impact did the number of employees have on the company Nykode Therapeutics A?

The number of employees has a direct impact on the efficiency and productivity of Nykode Therapeutics A. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Nykode Therapeutics A?

The number of employees can also have an impact on investors of Nykode Therapeutics A, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Nykode Therapeutics A affect the company?

An increase in equity of Nykode Therapeutics A can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Nykode Therapeutics A's equity affect the company?

A reduction in equity of Nykode Therapeutics A can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Nykode Therapeutics A?

Some factors that can influence the equity of Nykode Therapeutics A include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Nykode Therapeutics A so important for investors?

The equity of Nykode Therapeutics A is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Nykode Therapeutics A influence the company?

The number of employees at Nykode Therapeutics A can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Nykode Therapeutics A evolved in recent years?

In recent years, the number of employees at Nykode Therapeutics A has changed by 0.

How many employees does Nykode Therapeutics A currently have?

Nykode Therapeutics A currently has 36 undefined employees.

Why is the number of employees important for investors of Nykode Therapeutics A?

The number of employees is important for investors of Nykode Therapeutics A as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Nykode Therapeutics A take to change the number of employees?

To change the number of employees, Nykode Therapeutics A can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Nykode Therapeutics A pay?

Over the past 12 months, Nykode Therapeutics A paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Nykode Therapeutics A is expected to pay a dividend of 0 USD.

What is the dividend yield of Nykode Therapeutics A?

The current dividend yield of Nykode Therapeutics A is .

When does Nykode Therapeutics A pay dividends?

Nykode Therapeutics A pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nykode Therapeutics A?

Nykode Therapeutics A paid dividends every year for the past 0 years.

What is the dividend of Nykode Therapeutics A?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nykode Therapeutics A located?

Nykode Therapeutics A is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nykode Therapeutics A kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nykode Therapeutics A from 12/18/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Nykode Therapeutics A pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Nykode Therapeutics A in the year 2023?

In the year 2023, Nykode Therapeutics A distributed 0 USD as dividends.

In which currency does Nykode Therapeutics A pay out the dividend?

The dividends of Nykode Therapeutics A are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Nykode Therapeutics A

Our stock analysis for Nykode Therapeutics A Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nykode Therapeutics A Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.